Physician profile
Mark G Marrone
NPI 1003809575
$7,665.74
in general payments reported to CMS, 2019-2025
30 companies · $1,217 in 2025
The $1,217 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $879 · 2021: $946 · 2022: $1,115 · 2023: $1,027 · 2024: $1,086 · 2025: $1,217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,152 · Education: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,151.88 |
| Education | $177.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,027.90 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $662.36 | 2019-2025 | Farxiga |
| Travere Therapeutics, INC. | $602.23 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $586.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $483.01 | 2019-2025 | Jynarque |
| Alexion Pharmaceuticals, INC. | $402.07 | 2019-2025 | Ultomiris |
| Opko Pharmaceuticals, LLC | $397.20 | 2019-2025 | Rayaldee |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.63 | 2019-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $364.82 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $337.99 | 2020-2024 | Acthar |
| Fresenius USA Marketing, INC. | $328.42 | 2019-2025 | Velphoro |
| Mallinckrodt Enterprises LLC | $287.17 | 2019 | |
| Amgen INC. | $282.84 | 2019-2025 | Tavneos |
| Novartis Pharmaceuticals Corporation | $272.37 | 2024-2025 | |
| Akebia Therapeutics INC | $171.48 | 2019-2024 | Vafseo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $158.63 | 2019-2022 | |
| Calliditas Therapeutics US INC. | $157.32 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $157.03 | 2025 | |
| Ardelyx, INC. | $138.56 | 2024-2025 | Ibsrela |
| Pulmonx Corporation | $134.51 | 2022 | |
| Genzyme Corporation | $72.70 | 2019-2022 | |
| Glaxosmithkline, LLC. | $62.98 | 2021-2023 | Jesduvroq, Benlysta |
| Kyowa Kirin, INC. | $44.84 | 2024-2025 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $34.23 | 2025 | |
| Bard Peripheral Vascular, INC. | $29.35 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.50 | 2023 | Oxlumo |
| Cormedix INC. | $15.97 | 2025 | Defencath |
| Ultragenyx Pharmaceutical INC. | $15.50 | 2021 | |
| Ani Pharmaceuticals, INC. | $14.73 | 2023 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $14.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Marrone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.